162 related articles for article (PubMed ID: 8932455)
21. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
[TBL] [Abstract][Full Text] [Related]
22. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery.
Marchal-Heussler L; Sirbat D; Hoffman M; Maincent P
Pharm Res; 1993 Mar; 10(3):386-90. PubMed ID: 8464811
[TBL] [Abstract][Full Text] [Related]
23. Reduction of cardiovascular side effects associated with ocular administration of metipranolol by inclusion in polymeric nanocapsules.
Losa C; Alonso MJ; Vila JL; Orallo F; Martinez J; Saavedra JA; Pastor JC
J Ocul Pharmacol; 1992; 8(3):191-8. PubMed ID: 1360489
[TBL] [Abstract][Full Text] [Related]
24. Self-assembling colloidal system for the ocular administration of cyclosporine A.
Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
[TBL] [Abstract][Full Text] [Related]
25. Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.
Benítez del Castillo JM; Castillo A; Toledano N; Durán S; del Aguila C; Otero M; García-Sanchez J
Doc Ophthalmol; 1995; 91(1):49-55. PubMed ID: 8861636
[TBL] [Abstract][Full Text] [Related]
26. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
Kim ST; Jang DJ; Kim JH; Park JY; Lim JS; Lee SY; Lee KM; Lim SJ; Kim CK
Pharmazie; 2009 Aug; 64(8):510-4. PubMed ID: 19746839
[TBL] [Abstract][Full Text] [Related]
27. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN).
Ugazio E; Cavalli R; Gasco MR
Int J Pharm; 2002 Jul; 241(2):341-4. PubMed ID: 12100861
[TBL] [Abstract][Full Text] [Related]
28. Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
Calvo P; Alonso MJ; Vila-Jato JL; Robinson JR
J Pharm Pharmacol; 1996 Nov; 48(11):1147-52. PubMed ID: 8961163
[TBL] [Abstract][Full Text] [Related]
29. Formulation and evaluation of Cyclosporin A emulgel for ocular delivery.
Shen Y; Ling X; Jiang W; Du S; Lu Y; Tu J
Drug Deliv; 2015; 22(7):911-7. PubMed ID: 24401095
[TBL] [Abstract][Full Text] [Related]
30. Development of a new cyclosporine formulation based on poly(caprolactone) microspheres.
Aberturas MR; Molpeceres J; Guzmán M; García F
J Microencapsul; 2002; 19(1):61-72. PubMed ID: 11811760
[TBL] [Abstract][Full Text] [Related]
31. Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A.
Dai W; Guo Y; Zhang H; Wang X; Zhang Q
Int J Pharm; 2015 Jan; 478(2):718-25. PubMed ID: 25448562
[TBL] [Abstract][Full Text] [Related]
32. Quality by design: understanding the product variability of a self-nanoemulsified drug delivery system of cyclosporine A.
Zidan AS; Sammour OA; Hammad MA; Megrab NA; Habib MJ; Khan MA
J Pharm Sci; 2007 Sep; 96(9):2409-23. PubMed ID: 17628495
[TBL] [Abstract][Full Text] [Related]
33. Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine.
Gebhardt BM; Kaufman HE
J Ocul Pharmacol Ther; 1995; 11(3):319-27. PubMed ID: 8590264
[TBL] [Abstract][Full Text] [Related]
34. Porous magnesium aluminometasilicate tablets as carrier of a cyclosporine self-emulsifying formulation.
Sander C; Holm P
AAPS PharmSciTech; 2009; 10(4):1388-95. PubMed ID: 19936938
[TBL] [Abstract][Full Text] [Related]
35. Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.
Wolska E; Sznitowska M; Chorążewicz J; Szerkus O; Radwańska A; Markuszewski MJ; Kaliszan R; Raczyńska K
Eur J Pharm Sci; 2018 Aug; 121():95-105. PubMed ID: 29777856
[TBL] [Abstract][Full Text] [Related]
36. A novel use of an in vitro method to predict the in vivo stability of block copolymer based nano-containers.
Aliabadi HM; Brocks DR; Mahdipoor P; Lavasanifar A
J Control Release; 2007 Sep; 122(1):63-70. PubMed ID: 17644207
[TBL] [Abstract][Full Text] [Related]
37. Encapsulation of hydrophobic drugs in polymeric micelles through co-solvent evaporation: the effect of solvent composition on micellar properties and drug loading.
Aliabadi HM; Elhasi S; Mahmud A; Gulamhusein R; Mahdipoor P; Lavasanifar A
Int J Pharm; 2007 Feb; 329(1-2):158-65. PubMed ID: 17008034
[TBL] [Abstract][Full Text] [Related]
38. [Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats].
Wang XQ; Dai JD; Zhang Q; Zhang T; Xia GM
Yao Xue Xue Bao; 2004 Jun; 39(6):463-6. PubMed ID: 15491107
[TBL] [Abstract][Full Text] [Related]
39. Nanospheres of cyclosporin A: poor oral absorption in dogs.
Ford J; Woolfe J; Florence AT
Int J Pharm; 1999 Jun; 183(1):3-6. PubMed ID: 10361143
[TBL] [Abstract][Full Text] [Related]
40. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
Yu Y; Chen D; Li Y; Yang W; Tu J; Shen Y
Drug Deliv; 2018 Nov; 25(1):888-899. PubMed ID: 29631468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
